← Back to Search

Feraheme for Bone Cancer (Osteosarcoma Trial)

Phase 2

Waitlist Available

Led By Heike E Daldrup-Link, MD

Research Sponsored by Heike E Daldrup-Link

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 hours

Awards & highlights

Osteosarcoma Trial Summary

This trialuses MRI to help doctors more accurately distinguish between bone cancer and infection, to ensure patients get the right treatment quickly.

Eligible Conditions

Bone Cancer
Chondrosarcoma
Osteomyelitis
Osteonecrosis
Rhabdomyosarcoma
Bone Sarcoma
Ewing Sarcoma
Osteosarcoma

Osteosarcoma Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects

Secondary outcome measures

Differentiation of Bone Sarcomas Pre-ferumoxytol and Post-ferumoxytol Contrast

Differentiation of CD163-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas

Differentiation of CD68-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas

+1 more

Osteosarcoma Trial Design

1Treatment groups

Experimental Treatment

Group I: FerahemeExperimental Treatment2 Interventions

Intravenous injection of Feraheme, 5 mg Fe/kg

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ferumoxytol

FDA approved

Magnetic Resonance Imaging (MRI) scan

2013

Completed Phase 2

~1180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Heike E Daldrup-LinkLead Sponsor

1 Previous Clinical Trials

75 Total Patients Enrolled

Heike E Daldrup-Link, MDPrincipal InvestigatorStanford University

Neyssa Marina, MDPrincipal InvestigatorStanford University

Media Library

Magnetic Resonance Imaging (MRI) scan Clinical Trial Eligibility Overview. Trial Name: NCT01336803 — Phase 2

Bone Cancer Research Study Groups: Feraheme

Bone Cancer Clinical Trial 2023: Magnetic Resonance Imaging (MRI) scan Highlights & Side Effects. Trial Name: NCT01336803 — Phase 2

Magnetic Resonance Imaging (MRI) scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT01336803 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age bracket for this experiment include minors?

"This clinical trial is accepting participants between the age of 10 and 21."

Answered by AI

Has Feraheme been accorded official sanctioning by the FDA?

"Despite the fact that no evidence exists yet to confirm Feraheme's efficacy, there is still enough information backing its safety for it to receive a score of 2."

Answered by AI

Would I be qualified to participate in this research project?

"In order to qualify for this trial, patients must be between 10 and 21 years old and have been diagnosed with osteomyelitis. The study is searching for a total of 21 participants."

Answered by AI

Are there any historical examples of Feraheme being tested in a research setting?

"16 trials are presently underway to further assess the efficacy of Feraheme, 4 of which have reached Phase 3. While most experiments for this treatment take place in New york City, there is a presence at 41 different sites across the nation."

Answered by AI

Are participants able to join this trial at the present time?

"Unfortunately, no new patients can be admitted to this trial as the latest edition was made on May 30th 2019. However, if you are still interested in participating in a medical study related to osteomyelitis there currently 656 active trials and 16 studies actively admitting candidates for Feraheme treatment."

Answered by AI

What is the overall participation rate in this clinical trial?

"At this moment, the trial is not actively recruiting patients. The initial post was on August 1st 2011 and the latest edit occurred May 30th 2019. If you are searching for other trials, 656 studies related to osteomyelitis and 16 regarding Feraheme are open at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Heike E Daldrup-Link 2011. "Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01336803.